MEK inhibitors have shown potential in thyroid cancer treatment by enhancing iodine uptake and retention, inducing G0/G1 cell cycle arrest through reduced MEK/ERK phosphorylation, and inhibiting the viability of cells harboring BRAF mutations. This evidence concerns the gene BRAF and thyroid gland carcinoma.